drugset
Drugs / AAV-hAADC-2
last change Mar 2018 re-read 3 minutes ago

AAV-hAADC-2

Gene therapy (AAV / viral vector)

Developed for
Parkinson disease
Investigated by
Gene Therapy Research Institution,Co.,Ltd. · Genzyme, a Sanofi Company · Jichi Medical University · Takara Bio Inc.

Trials 2

today NCT02418598 · Ph 1/2 NCT00229736 · Ph 1
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00229736 Nov 2004 → Mar 2013 Parkinson disease Genzyme, a Sanofi Company Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02418598 Apr 2015 → Mar 2018 Parkinson disease Jichi Medical University Terminated No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as AAV-hAADC-2 “AAV-hAADC-2 is administered via bilateral intra-putaminal infusion.” NCT02418598 ↗
1

NCT00229736 ↗
Action Restore “AAV-hAADC-2 is intended to provide, directly to the brain, the missing enzyme needed to convert L-dopa to dopamine.” NCT00229736 ↗
Modality Gene therapy (AAV / viral vector) “the gene coding for the enzyme that converts L-dopa to dopamine (AADC) is inserted into a common, non-pathogenic virus (AAV)” NCT00229736 ↗
Route Other “AAV-hAADC-2, the investigational drug being studied, is injected into the striatum during a surgical procedure.” NCT00229736 ↗